🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

DNA damage response drugs for cancer yield continued synthetic lethality learnings go.nature.com/3PtOg6I A news article published today discussing the opportunities and challenges for anticancer drugs targeting PARP1, ATR and more

As a surge of cancer drugs with new synthetic lethality targets such as POLQ, USP1, PKMYT1 and PRMT5 enter the clinic, the opportunities and challenges of the underlying discovery strategies are coming into focus - read more in this news article go.nature.com/3zLZA9b

Julie Gerberding — incoming CEO of the Foundation for the NIH (FNIH), and former Director of the CDC and executive at Merck & Co. — discusses COVID-19 learnings, centralized clinical trials and trust in science in this new interview go.nature.com/3O1MaKm

COVID antibody drugs have saved lives — so why aren’t they more popular? go.nature.com/3OTzyoJ

Base editors hit the clinic go.nature.com/3PGys03 The first clinical trial of a drug designed to change a DNA base at a specific location has just started. Read about the base editor pipeline for cardiovascular and haematological diseases and the challenges for the field here

Already a few weeks old but still an excellent write-up by Asher Mullard about drug discovery efforts for synthetically lethal cancer targets: PolQ, USP1, PKMYT1, PRMT5, MAT2A & WRN1. Who will follow in the footsteps of PARP inhibitors? Nature Reviews Drug Discovery media.nature.com/original/magaz…

I'm still amazed by the accelerating pace of new modality drugs gaining approval. We've updated the chart from last year and are making it available for download and use in slides. [withdrawn drugs not shown, and yes, next solve access]. BioCentury. biocentury.com/article/644637

The UK Biobank at 20 go.nature.com/3zPqETf Naomi Allen, chief scientist of UK Biobank, which houses a collection of biological samples and health information from 500,000 volunteers, discusses the exploding body of findings on genetic drivers of disease from this resource

First de novo deuterated drug poised for approval go.nature.com/3C6n0ap Read about the first-in-class TYK2 inhibitor and blockbuster contender deucravacitinib and the pipeline of other drug candidates incorporating deuterium to improve their characteristics in this news article

Find out about the pipeline of drug candidates in which deuterium has been incorporated to improve their characteristics in this news story, which highlights deucravacitinib, a pioneering TYK2 inhibitor for psoriasis that is on the cusp of FDA approval go.nature.com/3PL19bJ

The FDA has approved deucravacitinib, a first-in-class TYK2 inhibitor for psoriasis that incorporates deuteurium in its structure bit.ly/3qCkaTj Find out more about the pipeline of deuterated drugs in this news article in the September issue go.nature.com/3RUco2X

Here’s the Atlas Venture 2022 Year In Review. This year, given the 2+ year rollercoaster in the mkts, we start with a deep dive into both the public and private #biotech capital markets, then to the industry overall, closing with an update on ⁦Atlas youtu.be/LONM9ekseJ4

Climbing cancer’s MYC mountain go.nature.com/3A9tSSm MYC, one of the most commonly dysregulated proteins in cancer, has long seemed ‘undruggable’. Can a clinical-stage cell-penetrating peptide — or preclinical small-molecule inhibitors and degraders — prove otherwise?

Thanks NRDD for this nice article! It is wonderful to see the response of the general scientific community to our clinical trials with a first-in-modality MYC inhibitor. Vall d’Hebron Institute of Oncology (VHIO) ICREA Community @Peptomyc #Omomyc #Omo103

Targeting #cMyc is a perfect showcase about the evolving modality-agnostic drug discovery innovation space. From cell-penetrating peptides to (ir)reversible NCEs to co-dependency harnessing GSPT1 degraders. Great write up as always by Asher Mullard nature nature.com/articles/d4157…

Taking the mick out of MYC: @Ashermullard on industry's efforts to drug the "undruggable" master regulator of cancer growth: nature.com/articles/d4157…

LRRK2-targeted Parkinson disease drug advances into phase III go.nature.com/3URjJS7 Biogen and Denali’s pivotal trial of a first-in-class LRRK2 kinase inhibitor is a long-awaited test of a target that could provide a path to disease-modifying therapies for Parkinson disease

If you are interested in background about yesterday's Nimbus Therapeutics Takeda megadeal for #Tyk2 pseudokinase domain inhibitor NDI-034858 (the term "allosteric" is a bit confusing), here is an excellent recent write-up by Elie Dolgin in Nature Biotechnology nature.com/articles/s4158…

my latest: Scientists tie third clinical trial death to experimental Alzheimer’s drug lecanemab - Amid lobbying for its approval by FDA, newly revealed death adds to doubts about safety of antiamyloid antibody science.org/content/articl…